Biofrontera Inc
Change company Symbol lookup
Select an option...
BFRI Biofrontera Inc
GOVT iShares U.S. Treasury Bond ETF
BAC Bank of America Corp
$NQASPA50JPYN Nasdaq ASPA Industrials Net Total Re
SNP China Petroleum & Chemical Corp
GAEC Gulf Alternative Energy Corp
RDBX Redbox Entertainment Inc
AFG American Financial Group Inc
MRNA Moderna Inc
PFE Pfizer Inc
Go

Company profile

Biofrontera Inc is a biopharmaceutical company. The Company is specialized in the commercialization of pharmaceutical products for the treatment of dermatological conditions for the diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its products focus on the treatment of actinic keratoses, which are skin lesions that lead to skin cancer. It also markets a topical antibiotic for treatment of impetigo, a bacterial skin infection. The Company’s principal product is Ameluz, which is a prescription drug for use in combination with its medical device, the BF-RhodoLED lamp, for photodynamic therapy (PDT) in the United States for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It offers Xepi for the treatment of impetigo, a common skin infection, due to Staphylococcus aureus or streptococcus pyogenes.

Closing Price
$7.90
Day's Change
2.68 (51.34%)
Bid
--
Ask
--
B/A Size
--
Day's High
9.49
Day's Low
6.58
Volume
(Heavy Day)
Volume:
103,361,385

10-day average volume:
31,078,694
103,361,385

Upcoming Events

BFRI's fiscal year ends in December
There are no upcoming events for BFRI

Past IPOs

DateEvent descriptionAmount of offeringNumber of sharesExpected price range
October 29, 2021Biofrontera Inc Initial Public Offering$1,800,000360,000$5.00 to $5.00

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

, , , Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.